Next Article in Journal
Analyzing Precision Medicine Utilization with Real-World Data: A Scoping Review
Next Article in Special Issue
Prognostic Significance of Perineural Invasion in Patients with Stage II/III Gastric Cancer Undergoing Radical Surgery
Previous Article in Journal
Targeting Cancer Stem Cells through Epigenetic Modulation of Interferon Response
Previous Article in Special Issue
Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients
Comment published on 29 June 2022, see J. Pers. Med. 2022, 12(7), 1061.
Article

Outcomes of Conversion Surgery for Metastatic Gastric Cancer Compared with In-Front Surgery Plus Palliative Chemotherapy or In-Front Surgery Alone

1
Department of General Surgery, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan
2
Department of Gastroenterology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan
3
Department of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Lorenza Rimassa
J. Pers. Med. 2022, 12(4), 555; https://doi.org/10.3390/jpm12040555
Received: 28 February 2022 / Revised: 27 March 2022 / Accepted: 30 March 2022 / Published: 1 April 2022
(This article belongs to the Special Issue Upper Digestive Surgical Oncology)
The survival benefits of conversion surgery in patients with metastatic gastric cancer (mGC) remain unclear. Thus, this study aimed to determine the outcomes of conversion surgery compared to in-front surgery plus palliative chemotherapy (PCT) or in-front surgery alone for mGC. We recruited 182 consecutive patients with mGC who underwent gastrectomy, including conversion surgery, in-front surgery plus PCT, and in-front surgery alone at Linkou Chang Gung Memorial Hospital from 2011 to 2019. The tumor was staged according to the 8th edition of the American Joint Committee on Cancer. Patient demographics and clinicopathological factors were assessed. Overall survival (OS) was evaluated using the Kaplan–Meier curve and compared among groups. Conversion surgery showed a significantly longer median OS than in-front surgery plus PCT or in-front surgery alone (23.4 vs. 13.7 vs. 5.6 months; log rank p < 0.0001). The median OS of patients with downstaging (pathological stage I–III) was longer than that of patients without downstaging (stage IV) (30.9 vs. 18.0 months; p = 0.016). Our study shows that conversion surgery is associated with survival benefits compared to in-front surgery plus PCT or in-front surgery alone in patients with mGC. Patients who underwent conversion surgery with downstaging had a better prognosis than those without downstaging. View Full-Text
Keywords: conversion surgery; metastatic gastric cancer; chemotherapy; outcomes conversion surgery; metastatic gastric cancer; chemotherapy; outcomes
Show Figures

Figure 1

MDPI and ACS Style

Huang, R.-Y.; Kou, H.-W.; Le, P.-H.; Kuo, C.-J.; Chen, T.-H.; Wang, S.-Y.; Chen, J.-S.; Yeh, T.-S.; Hsu, J.-T. Outcomes of Conversion Surgery for Metastatic Gastric Cancer Compared with In-Front Surgery Plus Palliative Chemotherapy or In-Front Surgery Alone. J. Pers. Med. 2022, 12, 555. https://doi.org/10.3390/jpm12040555

AMA Style

Huang R-Y, Kou H-W, Le P-H, Kuo C-J, Chen T-H, Wang S-Y, Chen J-S, Yeh T-S, Hsu J-T. Outcomes of Conversion Surgery for Metastatic Gastric Cancer Compared with In-Front Surgery Plus Palliative Chemotherapy or In-Front Surgery Alone. Journal of Personalized Medicine. 2022; 12(4):555. https://doi.org/10.3390/jpm12040555

Chicago/Turabian Style

Huang, Ruo-Yi, Hao-Wei Kou, Puo-Hsien Le, Chia-Jung Kuo, Tsung-Hsing Chen, Shang-Yu Wang, Jen-Shi Chen, Ta-Sen Yeh, and Jun-Te Hsu. 2022. "Outcomes of Conversion Surgery for Metastatic Gastric Cancer Compared with In-Front Surgery Plus Palliative Chemotherapy or In-Front Surgery Alone" Journal of Personalized Medicine 12, no. 4: 555. https://doi.org/10.3390/jpm12040555

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop